Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $19.3 million.

  • Gossamer Bio's Accumulated Expenses rose 10.72% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 10.72%. This contributed to the annual value of $15.2 million for FY2024, which is 43.08% down from last year.
  • Gossamer Bio's Accumulated Expenses amounted to $19.3 million in Q3 2025, which was up 23.65% from $15.6 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Accumulated Expenses high stood at $31.5 million for Q3 2022, and its period low was $14.3 million during Q2 2023.
  • For the 3-year period, Gossamer Bio's Accumulated Expenses averaged around $16.9 million, with its median value being $15.6 million (2025).
  • Examining YoY changes over the last 5 years, Gossamer Bio's Accumulated Expenses showed a top increase of 29.94% in 2023 and a maximum decrease of 45.63% in 2023.
  • Quarterly analysis of 4 years shows Gossamer Bio's Accumulated Expenses stood at $20.5 million in 2022, then rose by 29.94% to $26.7 million in 2023, then tumbled by 43.08% to $15.2 million in 2024, then increased by 10.72% to $19.3 million in 2025.
  • Its Accumulated Expenses was $19.3 million in Q3 2025, compared to $15.6 million in Q2 2025 and $14.8 million in Q1 2025.